Gastric Cancer in the Era of Precision Medicine.
Gastric Cancer in the Era of Precision Medicine.
复制标题
DOI：
10.1016/j.jcmgh.2017.02.003
复制
发表时间：
2017-05
影响因子：
7.2
通讯作者：
Meltzer SJ
中科院分区：
文献类型：
--
作者：
Liu X;Meltzer SJ
胃癌(GC)仍然是全球癌症死亡的第三大常见原因，可用的治疗策略有限。随着下一代测序和新的临床前模型技术的出现，我们对其发病机制和分子变化的理解继续发生着革命性的变化。最近，GC的基因组图谱已经被勾画出来。每个分子亚型的分子特征和新的治疗靶点已经确定。与此同时，患者来源的肿瘤异种移植和有机类化合物现在成为GC患者遗传进化研究、生物标记物识别、药物筛选和个性化药物策略的临床前评估的有效工具。这些进展使整合临床、基于基因组和基于表型的诊断和治疗方法并将其应用于精准医学时代的单个GC患者成为可能。
Gastric cancer (GC) remains the third most common cause of cancer death worldwide, with limited therapeutic strategies available. With the advent of next-generation sequencing and new preclinical model technologies, our understanding of its pathogenesis and molecular alterations continues to be revolutionized. Recently, the genomic landscape of GC has been delineated. Molecular characterization and novel therapeutic targets of each molecular subtype have been identified. At the same time, patient-derived tumor xenografts and organoids now comprise effective tools for genetic evolution studies, biomarker identification, drug screening, and preclinical evaluation of personalized medicine strategies for GC patients. These advances are making it feasible to integrate clinical, genome-based and phenotype-based diagnostic and therapeutic methods and apply them to individual GC patients in the era of precision medicine.